The Child and Adolescent Psychiatry Trials Network Announces Partnership with Clinipace to Streamline Clinical Research: Next Study to Examine Suicide Risks in Adolescents using Anti-Depressants

The Child and Adolescent Psychiatry Trials Network Announces Partnership with Clinipace to Streamline Clinical Research: Next Study to Examine Suicide Risks in Adolescents using Anti-Depressants



The Child and Adolescent Psychiatry Trials Network (CAPTN), a multi-national network of practicing child and adolescent psychiatrists established in partnership with Duke University and the American Academy of Child and Adolescent Psychiatry (AACAP), has chosen Clinipace’s web-based Tempo™ software platform to support its upcoming clinical research projects.



Durham, NC (PRWEB) October 25, 2006



The Child and Adolescent Psychiatry Trials Network (CAPTN), a multi-national network of practicing child and adolescent psychiatrists established in partnership with Duke University and the American Academy of Child and Adolescent Psychiatry (AACAP), has chosen Clinipace's web-based Tempo™ software platform to support its upcoming clinical research projects.



The next study, which is funded by the National Institute of Mental Health (NIMH) and will start in November of 2006, will examine the effects of SSRI and SNRI antidepressants in children and adolescents. CAPTN will use Clinipace's Tempo software to collect data on 2,420 youths over three years from more than 200 psychiatric practices in the U. S. and Canada. Additionally, CAPTN will use Tempo to collect and manage data on the psychiatric practices themselves in order to establish the generalizability of the trial findings and study how participation in research impacts the practitioner's clinical practice.



Given the prevalence of antidepressant use, and the FDA's determination that antidepressants cause suicidal thinking or behavior in some children and adolescents, there is a clear need to obtain better information about which children are at risk and which will benefit from antidepressant treatment.



"CAPTN has as one of its primary aims, to find innovative ways to simplify and facilitate clinical research in the context of normal medical practice. After extensive investigation of electronic systems, we concluded that the Tempo research platform was the most user-friendly. This innovative platform will help us to quickly deploy research studies in response to the clinical questions raised by our membership. The system is extremely simple to use, and we believe that simplicity is critical to our success," commented Mark Shapiro, leader of the CAPTN Coordinating Center at Duke University.



Shapiro continued, "After reviewing several systems, Clinipace's Tempo seemed to be superior in terms of scalability, flexibility, and ease-of-use. We expect that the intuitiveness of the interface will require only limited, self-directed training, thereby eliminating a major barrier to participation commonly cited by scientific investigators."



Jeff Williams, CEO of Clinipace, added, "Establishing a research network complete with technology infrastructure is a great way to efficiently conduct multiple research programs and foster real-time collaboration. We are excited to be supporting CAPTN, a very progressive and sophisticated network, as they investigate many important psychiatric issues, such as those at the heart of this landmark SSRI study."



About Clinipace



Clinipace is a clinical research software company providing a single, integrated data capture and study management platform for post-approval research and registries conducted by biopharmaceutical and medical device companies, Clinical Research Organizations (CROs) and Academic Medical Centers (AMCs). Our platform, called Tempo, is delivered via a web-based, on-demand architecture that streamlines the clinical research process by eliminating the integration headaches associated with multiple platforms, reducing project efforts and costs from startup to conclusion, and empowering project stakeholders to make informed real-time decisions regarding their research.



For more information on Clinipace, please visit: www. clinipace. com



About the Child and Adolescent Psychiatry Trials Network (CAPTN)



Led by Dr. John March, Professor and Chief of Child and Adolescent Psychiatry at Duke University School of Medicine, CAPTN is a partnership between the American Academy of Child & Adolescent Psychiatry and the Duke Clinical Research Institute. CAPTN is clinical research network of more than 200 child and adolescent psychiatrists from the United States and Canada working collaboratively to conduct innovative clinical research that will increase knowledge about the effectiveness and safety of approved medications that are widely used, either alone or in combination, to treat youth with mental illness.



For more information or to join CAPTN, please visit: www. captn. org



###

You have read this article health with the title The Child and Adolescent Psychiatry Trials Network Announces Partnership with Clinipace to Streamline Clinical Research: Next Study to Examine Suicide Risks in Adolescents using Anti-Depressants. You can bookmark this page URL https://ysagabriellechong.blogspot.com/2008/12/the-child-and-adolescent-psychiatry.html?m=0. Thanks!